Personalized Medicine: 2021 FDA Guideposts for Progress - Focus on Therapeutics

03 March 2022 Personalized Medicine Bulletin Blog
Author(s): Antoinette F. Konski

The Personalized Medicine Coalition (PMC) released PERSONALIZED MEDICINE AT FDA: The Scope & Significance of Progress in 2021 (2021 Report), its recent survey of U.S. Food and Drug Administration (FDA)-approved personalized therapies and diagnostic tests that enable those therapies. The 2021 Report highlights that personalized medicines accounted for over a third of new drug approvals in 2021 and 25% or more of all FDA approvals for each of the last seven years.1

2021 FDA Guideposts

2021 FDA Therapeutic Approvals

Seventeen new molecular entities (NMEs)2 and new two cell-based therapies approved by FDA in 2021 were personalized therapies.3

2021 FDA Guideposts

The approved NMEs treat:4 1. HIV (Cabenuva); 2. metastatic non-small cell lung cancer (Tepmetko); 3. familial hypercholesterolemia (Evkeeza); 4. Duchenne muscular dystrophy (Amondys); 5. molybdenum cofactor deficiency (Nulibry); 6. recurrent or advanced endometrial cancer (Jemperli); 7. locally advanced or metastatic non-small cell lung cancer (Rybrevant); 8. locally advanced or metastatic non-small cell lung cancer (Lumakras); 9. locally advanced or metastatic cholangiocarcinoma (Rybrevant); 10. prutitis in patients with progressive familial intrahepatic cholestasis (Bylvay); 11. Pompe disease (Nexviazyme); 12. von Hippel-Lindau disease (Welireg); 13. locally advanced or metastatic non-small cell lung cancer (Exkivity); 14. active severe vasculitis in combination with standard therapies such as glucocorticoids (Tavneos); 15. chronic myeloid leukemia in chronic phase (Scemblix); 16. generalized myasthenia gravis (Vyvgart); and 17. heterozygous familial hypercholesterolemia (Leqvio).

Two T cell-based CAR (chimeric antigen receptor) immune therapies were also approved. Breyanzi is an autologous CD-19 CAR T-cell therapy for the treatment of relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.  Abecma is an autologous modified BCMA (B-cell maturation antigen) targeted CAR T-cell therapy that treats relapsed or refractory multiple myeloma.

In addition to these therapies, many new personalized medicine indications were approved for existing drugs and drug combinations.5 Significant among the new approvals are: 1. Tecartus, the first approved CAR T-cell therapy for adult suffering from refractory B-cell precursor acute lymphoblastic leukemia (ALL); and 2. Leqvio, the 4th approved siRNA molecular therapy that targets and silences a portion of RNA involved in causing disease.

Continued Influence on America’s Health Care

The evolution and adoption of personalized or precision medicine can be measured by the growing number of FDA-approved therapies and the expansion to new indications of previously approved therapies. The 2021 Report highlights the growing importance and acceptance of precision medicine through the years. While the 2021 Report acknowledges that challenges remain in the areas of discovery, regulatory policy, coverage, reimbursement, and clinical adoption, personalized medicine is expected to “improve outcomes for patients and have a tremendous impact on the efficacy and efficiency of health care."6



1 PMC categorizes personalized medicines as those therapeutic products for which the label includes reference to specific biological markers that are often identified by diagnostic tools, that guide decisions and/or procedures for their use in individual patients.

2 The FDA categorizes a new molecular entity as a product that contains active moieties that FDA had not previously approved, either as a single ingredient drug or as part of a combination product. Some drugs are characterized as NMEs for administrative purposes, but nonetheless contain active moieties that are closely related to active moieties in products that FDA has previously approved. FDA’s classification of a drug as an “NME” for review purposes is distinct from FDA’s determination of whether a drug product is a “new chemical entity” or “NCE” within the meaning of the Federal Food, Drug, and Cosmetic Act.

3 2021 Report, page 12.

4 2021 Report, pages 7-8.

5 2021 Report, page 9 for a list of the new indications for approved therapies, including for example Keytruda and Rituxan.

6 2021 Report, page 17.

This blog is made available by Foley & Lardner LLP (“Foley” or “the Firm”) for informational purposes only. It is not meant to convey the Firm’s legal position on behalf of any client, nor is it intended to convey specific legal advice. Any opinions expressed in this article do not necessarily reflect the views of Foley & Lardner LLP, its partners, or its clients. Accordingly, do not act upon this information without seeking counsel from a licensed attorney. This blog is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Communicating with Foley through this website by email, blog post, or otherwise, does not create an attorney-client relationship for any legal matter. Therefore, any communication or material you transmit to Foley through this blog, whether by email, blog post or any other manner, will not be treated as confidential or proprietary. The information on this blog is published “AS IS” and is not guaranteed to be complete, accurate, and or up-to-date. Foley makes no representations or warranties of any kind, express or implied, as to the operation or content of the site. Foley expressly disclaims all other guarantees, warranties, conditions and representations of any kind, either express or implied, whether arising under any statute, law, commercial use or otherwise, including implied warranties of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Foley or any of its partners, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (contract, tort, negligence or otherwise), to you or anyone else, for any claims, losses or damages, direct, indirect special, incidental, punitive or consequential, resulting from or occasioned by the creation, use of or reliance on this site (including information and other content) or any third party websites or the information, resources or material accessed through any such websites. In some jurisdictions, the contents of this blog may be considered Attorney Advertising. If applicable, please note that prior results do not guarantee a similar outcome. Photographs are for dramatization purposes only and may include models. Likenesses do not necessarily imply current client, partnership or employee status.